论文部分内容阅读
[目的]探讨雄激素受体(AR)、人体抑癌基因p53在三阴性乳腺癌(triple-negative breast cancer,TNBC)中的表达及其意义.[方法]收集2010年1月至2011年12月本院诊治的87例TNBC患者(三阴组)和231例非TNBC患者(非三阴组)的临床资料,采用免疫组化法检测两组AR、p53的表达,并分析其与临床病理特征和预后的关系.[结果]三阴组患者p53和AR的阳性表达率分别为49.43％ (43/87)和37.93％(33/87),明显高于非三阴组的33.77％(78/23])和27.3％(63/231),其差异均有统计学意义(x2=9.451,P=0.025;x2 =8.287,P=0.031);AR阳性表达与淋巴结转移相关(P＜0.05);p53阳性表达与组织学分级和分子类型相关(P＜0.05),而其他指标与p53、AR阳性表达均不相关(P＞0.05);三阴组患者5年局部复发率和远处转移率显著高于非三阴组患者(P＜0.05),5年生存率显著低于非三阴组患者(P＜0.05).[结论]TNBC中p53和AR的表达上调,与肿瘤细胞分化程度、淋巴结转移状态相关;p53和AR可作为乳腺癌患者预后的预测指标.“,”[Objective] To investigate the relationship between the expression of androgen receptor and p53 in the prognosis of three negative breast cancer.[Methods]From January 2010 to December 2011,the clinical data of 87 patients with TNBC (three negative group) and 231 patients without TNBC (non-three negative group) were collected.The expression of AR and p53 was detected by immunohistochemistry and its relationship with clinicopathological features and prognosis was analyzed.[Results]The positive rates of p53 and AR in the three negative group were 49.43 ％ (43/87) and 37.93 ％ (33/87),respectively,which were significantly higher than those in the non-three negative group p 33.77 ％ (78/231) and 27.3 ％ (63/231),the differences were statistically significant(x2 =9.451,P =0.025;x2 =8.287,P =0.031).The positive expression of AR was related to lymph node metastasis (P ＜0.05),the positive expression of p53 was related to histological grade and molecular type (P ＜0.05),there was no correlation between other markers and the positive expression of p53 and AR (P ＞0.05).The 5-year local recurrence rate and distant metastasis rate in the three negative group was significantly higher than those in the non-three negative group (P ＜ 0.05).The 5-year survival rate was significantly lower than that in non-three negative group (P ＜0.05).[Conclusion] The expression of p53 and AR in TNBC was up-regulated,which was related to the differentiation of tumor cells and the status of lymph node metastasis,p53 and AR can be used as predictors of prognosis in patients with breast cancer.